Title: Is High-Dose Oseltamivir Indicated for Critically Ill Patients?
标题：高剂量的奥司他韦适用于危重病人吗？
Author作者: Bryan Hayes
翻译 ：于璐 何磊磊 校对： 陈都 肖锋
Despite the lack of strong evidence to support the recommendation, the severity of the 2009 influenza pandemic prompted the World Health Organization (WHO) to advise that higher doses of oseltamivir (150 mg twice daily) and longer treatment regimens (> 5 days) should be considered when treating severe or progressive illness.
尽管缺乏强有力的证据支持， 2009年流感大流行的严重程度仍然促使世界卫生组织（WHO）建议在治疗严重或恶化性疾病考虑使用高剂量的奥司他韦（150毫克，每日两次）和更长的治疗时间（大于5天）。
So, does the data support higher dosing in critically ill influenza patients?
那么，研究数据是否支持针对流感危重患者使用更高剂量的奥司他韦？
A new systematic review concluded that "the small body of literature available in humans does not support routine use of high-dose oseltamivir in critically ill patients."
一个新的系统评价得出的结论是：“非常少的有关人身上试验的文献不支持对危重患者常规使用高剂量的奥司他韦”。
References参考文献：
Flannery AH, et al. Oseltamivir dosing in critically ill patients with severe influenza. Ann Pharmacother 2014;48(8):1011-8. [PMID 24816209]